Grifols, S.A. Class A GRF
BME · Spain · Health Technology
€9.57+0.02 (+0.25%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple. The group’s ability to turn its plasma based operations into...
European equities traded in the US as American depositary receipts were tracking modestly higher lat
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.